Inventiva S.A. (IVA)
NASDAQ: IVA · Real-Time Price · USD
5.36
-0.01 (-0.19%)
At close: Sep 9, 2025, 4:00 PM
5.37
+0.01 (0.19%)
After-hours: Sep 9, 2025, 7:19 PM EDT

Company Description

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally.

The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.

It also develops TGF-β, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.

Inventiva S.A.
Inventiva logo
CountryFrance
Founded2011
IPO DateJul 10, 2020
IndustryBiotechnology
SectorHealthcare
Employees118
CEOFrederic Cren

Contact Details

Address:
50 rue de Dijon
Daix, 21121
France
Phone33 3 80 44 75 00
Websiteinventivapharma.com

Stock Details

Ticker SymbolIVA
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyEUR
IPO Price$14.40
CIK Code0001756594
CUSIP Number46124U107
ISIN NumberUS46124U1079
SIC Code2834

Key Executives

NamePosition
Frederic CrenCo-Founder, Chief Executive Officer and Director
Dr. Pierre Broqua Ph.D.Co-Founder
Dr. Martine Zimmermann Pharm.D.Executive Vice President of Regulatory Affairs and Quality Assurance and Director
Jean VolatierDeputy GM and Chief Financial Officer
Alice Roudot-Ketelers Pharm.D.Chief Operating Officer
Eric Duranson L.L.M.General Counsel
Nathalie HarroyHead of Human Resources
Pascaline Clerc Ph.D.Executive Vice President of Strategy and Corporate Affairs
Dr. Jason A. Campagna M.D., Ph.D.President of Research and Development and Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Aug 14, 2025SCHEDULE 13G/AFiling
Jul 31, 2025SCHEDULE 13G/AFiling
Jul 29, 20256-KReport of foreign issuer
Jul 9, 20256-KReport of foreign issuer
Jul 7, 20256-KReport of foreign issuer
Jun 20, 2025SCHEDULE 13GFiling
May 23, 20256-KReport of foreign issuer
May 23, 20256-KReport of foreign issuer
May 22, 20256-KReport of foreign issuer
May 15, 2025SCHEDULE 13GFiling